BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 19064568)

  • 1. Genetic and epigenetic alterations of familial pancreatic cancers.
    Brune K; Hong SM; Li A; Yachida S; Abe T; Griffith M; Yang D; Omura N; Eshleman J; Canto M; Schulick R; Klein AP; Hruban RH; Iacobuzio-Donohue C; Goggins M
    Cancer Epidemiol Biomarkers Prev; 2008 Dec; 17(12):3536-42. PubMed ID: 19064568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
    Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
    Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival.
    Shin SH; Kim SC; Hong SM; Kim YH; Song KB; Park KM; Lee YJ
    Pancreas; 2013 Mar; 42(2):216-22. PubMed ID: 23344532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adenosquamous carcinoma of the pancreas harbors KRAS2, DPC4 and TP53 molecular alterations similar to pancreatic ductal adenocarcinoma.
    Brody JR; Costantino CL; Potoczek M; Cozzitorto J; McCue P; Yeo CJ; Hruban RH; Witkiewicz AK
    Mod Pathol; 2009 May; 22(5):651-9. PubMed ID: 19270646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term survivors of pancreatic adenocarcinoma show low rates of genetic alterations in KRAS, TP53 and SMAD4.
    Masetti M; Acquaviva G; Visani M; Tallini G; Fornelli A; Ragazzi M; Vasuri F; Grifoni D; Di Giacomo S; Fiorino S; Lombardi R; Tuminati D; Ravaioli M; Fabbri C; Bacchi-Reggiani ML; Pession A; Jovine E; de Biase D
    Cancer Biomark; 2018 Feb; 21(2):323-334. PubMed ID: 29103024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Translational research in pancreatic cancer: KRAS and beyond.
    Boeck S; Ormanns S; Haas M; Bächmann S; Laubender RP; Siveke JT; Jung A; Kirchner T; Heinemann V
    Pancreas; 2014 Jan; 43(1):150-2. PubMed ID: 24326376
    [No Abstract]   [Full Text] [Related]  

  • 7. Relative role of methylator and tumor suppressor pathways in ulcerative colitis-associated colon cancer.
    Sanchez JA; Dejulius KL; Bronner M; Church JM; Kalady MF
    Inflamm Bowel Dis; 2011 Sep; 17(9):1966-70. PubMed ID: 21618350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variant Profiling of Candidate Genes in Pancreatic Ductal Adenocarcinoma.
    Huang J; Löhr JM; Nilsson M; Segersvärd R; Matsson H; Verbeke C; Heuchel R; Kere J; Iafrate AJ; Zheng Z; Ye W
    Clin Chem; 2015 Nov; 61(11):1408-16. PubMed ID: 26378065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.
    Oshima M; Okano K; Muraki S; Haba R; Maeba T; Suzuki Y; Yachida S
    Ann Surg; 2013 Aug; 258(2):336-46. PubMed ID: 23470568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Effect of Driver Mutations of
    Gu Y; Ji Y; Jiang H; Qiu G
    Genet Test Mol Biomarkers; 2020 Dec; 24(12):777-788. PubMed ID: 33347393
    [No Abstract]   [Full Text] [Related]  

  • 11. Immortalizing the complexity of cancer metastasis: genetic features of lethal metastatic pancreatic cancer obtained from rapid autopsy.
    Embuscado EE; Laheru D; Ricci F; Yun KJ; de Boom Witzel S; Seigel A; Flickinger K; Hidalgo M; Bova GS; Iacobuzio-Donahue CA
    Cancer Biol Ther; 2005 May; 4(5):548-54. PubMed ID: 15846069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma.
    Kawesha A; Ghaneh P; Andrén-Sandberg A; Ograed D; Skar R; Dawiskiba S; Evans JD; Campbell F; Lemoine N; Neoptolemos JP
    Int J Cancer; 2000 Nov; 89(6):469-74. PubMed ID: 11102889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KRAS2 mutations in human pancreatic acinar-ductal metaplastic lesions are limited to those with PanIN: implications for the human pancreatic cancer cell of origin.
    Shi C; Hong SM; Lim P; Kamiyama H; Khan M; Anders RA; Goggins M; Hruban RH; Eshleman JR
    Mol Cancer Res; 2009 Feb; 7(2):230-6. PubMed ID: 19208745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pancreatic ductal adenocarcinomas from Mexican patients present a distinct genomic mutational pattern.
    Sanchez P; Espinosa M; Maldonado V; Barquera R; Belem-Gabiño N; Torres J; Cravioto A; Melendez-Zajgla J
    Mol Biol Rep; 2020 Jul; 47(7):5175-5184. PubMed ID: 32583281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Roles of Frequently Mutated Genes of Pancreatic Cancer in Regulation of Tumor Microenvironment.
    Sun H; Zhang B; Li H
    Technol Cancer Res Treat; 2020; 19():1533033820920969. PubMed ID: 32372692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma.
    Sinn BV; Striefler JK; Rudl MA; Lehmann A; Bahra M; Denkert C; Sinn M; Stieler J; Klauschen F; Budczies J; Weichert W; Stenzinger A; Kamphues C; Dietel M; Riess H
    Pancreas; 2014 May; 43(4):578-83. PubMed ID: 24681874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitive and quantitative detection of KRAS2 gene mutations in pancreatic duct juice differentiates patients with pancreatic cancer from chronic pancreatitis, potential for early detection.
    Shi C; Fukushima N; Abe T; Bian Y; Hua L; Wendelburg BJ; Yeo CJ; Hruban RH; Goggins MG; Eshleman JR
    Cancer Biol Ther; 2008 Mar; 7(3):353-360. PubMed ID: 18075308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ki-ras and p53 mutations in pancreatic ductal adenocarcinoma.
    Rall CJ; Yan YX; Graeme-Cook F; Beauchamp R; Yandell DW; Povoski SP; Rustgi AK
    Pancreas; 1996 Jan; 12(1):10-7. PubMed ID: 8927612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Genetic aspects of pancreatic cancer].
    Grigor'eva IN; Efimova OV; Suvorova TS; Tov NL
    Eksp Klin Gastroenterol; 2014; (10):70-6. PubMed ID: 25911935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution and dynamics of pancreatic cancer progression.
    Yachida S; Iacobuzio-Donahue CA
    Oncogene; 2013 Nov; 32(45):5253-60. PubMed ID: 23416985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.